Sagility’s shares, trading at ₹43.47, have drawn a bullish 39% upside after Nuvama set a ₹60 target and issued a buy rating.
Nuvama values Sagility at 18 times its estimated FY28‑29 earnings per share, while EBITDA margins are projected to stay between 24% and 25%. The brokerage also notes strong free‑cash‑flow generation that should move the company into net‑cash status this financial year.
In an industry where AI is reshaping healthcare BPO, US outsourcing spend is projected to reach $259 billion by 2028, up from $201 billion in 2023, according to Nuvama. This trend underpins Sagility’s growth narrative.
CEO Ramesh Gopalan told CNBC‑TV18 that pressure on US payers keeps outsourcing demand high, and he reaffirmed the firm’s low‑double‑digit organic growth target for FY27, citing robust Q3 visibility despite a uncertain Q4.
Shares rose 2.2% to ₹44.04 earlier today, then steadied at ₹43.47—a 0.9% gain—though the stock has slipped 17% year‑to‑date.
With FY27 guidance in place and a projected 13% CAGR in USD revenue through 2029, Sagility is poised to transition into a net‑cash generator this year, positioning it favorably for the coming quarter.